Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VetoquinolVETOF 94 EV-to-EBITDA is 5.37 as of Aug. 04, 2026, which is 41% below its 10-year median of 9.17. GuruFocus rates VETOF with a GF Score™ of 94/100 and a GF Value™ of $108.39. The stock has 1 warning sign investors should review. Among 746 Drug Manufacturers companies, Vetoquinol ranks better than 84.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vetoquinol's enterprise value is $724.7 Mil.
Vetoquinol's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $134.9 Mil. Therefore, Vetoquinol's EV-to-EBITDA for today is 5.37.
The historical rank and industry rank for Vetoquinol's EV-to-EBITDA or its related term are showing as below:
VETOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1 Med: 9.17 Max: 21.87
Current: 5.39
During the past 13 years, the highest EV-to-EBITDA of Vetoquinol was 21.87. The lowest was 5.10. And the median was 9.17.
VETOF's EV-to-EBITDA is ranked better than 84.45% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.08
vs VETOF: 5.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vetoquinol's share price for today is $90.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vetoquinol's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.747.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vetoquinol's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vetoquinol EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vetoquinol's EV-to-EBITDA falls into.
Vetoquinol's current Enterprise Value is $724.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vetoquinol's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $134.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vetoquinol (VETOF) has a EV-to-EBITDA of 5.37 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vetoquinol. This is 41% below median its historical median of 9.17. Over the past decade, Vetoquinol's EV-to-EBITDA has ranged from 5.10 to 21.87. According to the industry distribution chart, Vetoquinol ranks #116 out of 746 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Vetoquinol's EV-to-EBITDA too high?
Vetoquinol's current EV-to-EBITDA of 5.37 is 41% below median its 10-year median of 9.17. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 21.87. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. Vetoquinol's value of 5.37 is 58.9% below this industry median. Based on the distribution chart, Vetoquinol ranks #116 out of 746 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vetoquinol has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Vetoquinol's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vetoquinol ranks #116 out of 746 companies for EV-to-EBITDA. This places Vetoquinol in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.08. Vetoquinol's value of 5.37 is 58.9% below this benchmark. Historically, Vetoquinol's own EV-to-EBITDA has ranged from 5.10 to 21.87 over the past decade. While the company's 10-year median is 9.17 vs. the industry median of 13.08, Vetoquinol has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vetoquinol's current EV-to-EBITDA of 5.37 is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vetoquinol. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vetoquinol's current EV-to-EBITDA is 5.37, which is 41% below median its own 10-year median of 9.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vetoquinol stock overvalued right now?
Vetoquinol (VETOF) has a current EV-to-EBITDA of 5.37. The stock's GF Value™ is $108.39, compared to a current price of $90.80 — trading 16.2% below its estimated fair value. The current EV-to-EBITDA is 5.37, which is 41% below median its 10-year median of 9.17 and 58.9% below the Drug Manufacturers industry median of 13.08. Vetoquinol's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vetoquinol (VETOF), the current EV-to-EBITDA is 5.37 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vetoquinol (VETOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued.
The current stock price of $90.80 is trading 16.2% below its estimated GF Value™ of $108.39.
Key valuation signals for VETOF:
EV-to-EBITDA: 5.37 (41% below median its 10-year median of 9.17)
GF Value™: $108.39 vs. price of $90.80 (16.2% below fair value)
Industry Position: 58.9% below the Drug Manufacturers median (#116 of 746)
No single metric tells the full story. See the VETOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
94GF Score
Get the complete analysis for VETOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VETOF has been successfully added to your 
